jingyao liu

Dr. jingyao liu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
AWAnxin Wang
Anxin Wang
XMXia Meng
Xia Meng
XTXue Tian
Xue Tian
SJS. Claiborne Johnston
S. Claiborne Johnston
HLHao Li
Hao Li
CICHANCE-2 Investigators
CHANCE-2 Investigators

9 December 2022 in Medicine
Verified
Journal Article
Open access
HZHui Zhu
Hui Zhu
JLjingyao liu
jingyao liu
The last 2 decades have witnessed considerable advances in our understanding of thrombotic thrombocytopenic purpura (TTP). However, there is still some ambiguity regarding the precise nature of this disease, especially with respect to nervous system involvement and the correct nomenclature. This article seeks to summarize the clinical manifestations of TTP and the associated diseases. We describe TTP complicated with cerebrovascular disease, spinal cord injury, posterior reversible encephalopathy syndrome (PRES), anxious-depressive symptoms, and cognitive decline. TTP with spinal cord injury is rarely reported. For better clarity, we discuss the case of a 57-year-old woman who was diagnosed with neuromyelitis optica spectrum disease (NMOSD) with atypical TTP. The concurrent occurrence of NMOSD and TTP in this patient is consistent with the characteristics of acquired autoimmunity. We highlight the importance of early recognition of TTP in patients with atypical presentation who may not have the expected clinical or laboratory findings. This is particularly important in TTP patients with other concomitant autoimmune diseases or age-related comorbid conditions.

1 January 2018 in Clinical Laboratory
Verified
Journal Article
Closed access
HZHui Zhu
Hui Zhu
TZTeng Zhao
Teng Zhao
JLjingyao liu
jingyao liu
Background: Paraoxonasel (PON1) is an antioxidant which confers antioxidant properties to high-density lipoprotein (HDL) and prevents low-density lipoprotein (LDL) oxidation. The purpose of this study was to evaluate the activities of PON1 and oxidative/antioxidative stress markers in acute cerebral infarction. Methods: In this study, 161 patients diagnosed with acute cerebral infarction and 161 gender- and age-matched healthy controls were recruited. Based on the clinicoradiological profiles, the patients were further classified into two groups: lacunar infarction group and large-artery atherosclerosis group. We measured the individual lipid status parameters, oxidative and antioxidative stress status parameters, and PON1 activity. Results: Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and oxidative stress parameters in patients with acute cerebral infarction were significantly higher than those in the normal controls (p < 0.05). High-density lipoprotein cholesterol (HDL-C) level, PON1 activity, superoxide dismutase (SOD) activity, and antioxidative stress parameters in patients were lower than in the normal controls (p < 0.05). Superoxide anion (O-2), malondialdehyde (MDA), and PON1 levels in the lacunar infarction group were lower than in the large-artery atherosclerosis group (p < 0.05). Conclusions: Oxidative stress markers and PON1 activity are sensitive indicators of acute cerebral infarction. Our findings suggest a severely impaired antioxidative protection mechanism in these patients. Our study provides new insights into the pathophysiological mechanisms of acute cerebral infarction, which may also provide new therapeutic targets for ischemic cerebrovascular diseases.

4 September 2014 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
HZHui Zhu
Hui Zhu
YGYingjie Guo
Yingjie Guo
XFXuemin Feng
Xuemin Feng
RZRensheng Zhang
Rensheng Zhang
CZChunkui Zhou
Chunkui Zhou
JLjingyao liu
jingyao liu

12 November 2018 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
XFXuemin Feng
Xuemin Feng
HZHui Zhu
Hui Zhu
TZTeng Zhao
Teng Zhao
YHYanbo Hou
Yanbo Hou
JLjingyao liu
jingyao liu
Objectives: In this study, we report a case of Finnish gelsolin amyloidosis (FGA) in a Chinese family.Methods: The proband presented with a range of clinical symptoms that included epileptic seizures and multiple lesions in the brain. Whole exome sequencing of the Gelsolin (GSN) gene was performed, and the GSN mutation was identified through comparison with the known human genome sequences using Genetic Testing Intelligent Execution System.Results: The GSN gene sequencing revealed that a heterozygous G duplicate in exon1 (c.100dupG) of the GSN gene, which caused a frameshift in GSN transcript translation in the proband, his mother and daughter, but his brother did not have it.Conclusion: We presented a new autosomal dominant heterozygous G duplicate mutation in exon1 of GSN gene, leading to FGA in a Chinese family.

13 November 2015 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
JLjingyao liu
jingyao liu
MLMin Li
Min Li
GLGuibo Li
Guibo Li
CZChunkui Zhou
Chunkui Zhou
RZRensheng Zhang
Rensheng Zhang
This study describes the case of a 41-year-old woman admitted for anterograde memory loss, right facial grimacing and right arm posturing that had begun 1 month previously. Cranial magnetic resonance-diffusion weighted imaging and -fluid-attenuated inversion recovery imaging revealed a hyperintense signal in the left hippocampus and right basal ganglia, but no contrast enhancement. An electroencephalogram revealed rhythmic sharp and slow waves and rhythmic θ build-ups in the left temporal area. Single-photon emission computed tomography showed increased regional blood flow perfusion in the left cerebral frontal lobe and the right basal ganglia. The cerebrospinal fluid was normal, with the exception of the presence of leucine-rich glioma-inactivated 1 (LGI1) antibodies, and LGI1 antibodies were also found in the blood serum. The presence of the antibodies, the faciobrachial dystonic seizures (FBDSs) and the memory loss indicated limbic encephalitis. After 3 months of immunotherapy, the patient was free from epileptic seizures and had undergone a partial memory restoration. FBDSs alone justify the immediate initiation of immunotherapy, even prior to laboratory confirmation of the disease, as early treatment limits the duration of the illness.